ID   ME-2
AC   CVCL_RL95
DR   cancercelllines; CVCL_RL95
DR   Wikidata; Q54904902
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8018932;
CC   Population: Japanese.
CC   Doubling time: 2-3 days (PubMed=8018932).
CC   Sequence variation: Gene fusion; HGNC; HGNC:1539; CBFB + HGNC; HGNC:7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2110 ! ME-1 [Human leukemia]
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 19-12-24; Version: 11
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=8018932; DOI=10.1182/blood.V84.1.84.84;
RA   Yanagisawa K., Sato M., Horiuchi T., Hasegawa H., Fujita S.;
RT   "Difference in response to colony-stimulating factors and involvement
RT   of protein kinase C signal transduction system in three subclones from
RT   the ME-1 cell line and two sublines.";
RL   Blood 84:84-93(1994).
//